Search

everythinglearnresearchcommunity

for

Search:↓

The COVID-19 pandemic led to fewer dermatology patients, more stress-related skin conditions during the crisis, and a rise in contact dermatitis after, with ongoing concerns for public health and treatment delays.

The congress showed that psychological therapy can help skin condition patients, social media affects acne stigma, education improves atopic dermatitis, and patient satisfaction in dermatology is high, especially with good doctor engagement.

Topical treatments can deliver active molecules to skin stem cells, potentially helping treat skin and hair disorders, including skin cancers and hair loss.

Alopecia causes significant emotional distress and psychological issues, requiring combined skin and mental health treatment.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

A woman's complete hair loss condition improved after recovering from COVID-19.

Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.

Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Polymeric microneedles offer a less invasive, long-lasting drug delivery method that improves patient compliance and reduces side effects.

Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.

The book explains how stem cells and PRP can treat various medical conditions.

Many patients with various medical conditions experience anxiety, which worsens their quality of life and raises healthcare costs.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

The study concludes that regulating apoptosis could lead to new treatments for various skin and hair conditions.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.

Minoxidil injections can speed up hair regrowth in non-severe patchy hair loss, but combining it with steroids doesn't improve results.

Increased HIF-1α is linked to the inflammation and severity of hidradenitis suppurativa, suggesting treatments that lower HIF-1α could help.

Adolescents with severe alopecia incur significantly higher healthcare costs.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

Topical tacrolimus did not regrow hair in alopecia universalis patients.

Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.

A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.

Some vitamins and minerals like vitamin D and iron can help with certain types of hair loss, but more research is needed for others.

Tattooing helps treat skin conditions, reconstruct nipple-areola, mark radiation fields, and locate lesions.

There may be a link between Helicobacter pylori infection and the skin condition pityriasis versicolor.

A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.